Introduction
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45
The PTEN gene is at least partially deleted in 10-30% of prostate cancer tumor samples and predicts poor 46 clinical outcomes [5] [6] [7] [8] . ENTPD5 is also overexpressed in p53 gain-of-function mutations through interaction of Mut-p53 with Sp1 ENTPD5's promoter region [9] .
48

Fig 1. ENTPD5 is an ER-resident UDPase important for proper glycoprotein folding.
49
Schematic diagram highlighting the role ENTPD5 plays in the glycoprotein refolding cycle in the ER. For
50
proper glycoprotein folding to occur, UDP-glucose is brought into the ER by an antiporter that uses UMP as the 51 counter molecule. ENTPD5 activity produces UMP, leading to increased levels of UDP-glucose entering the ER for 52 glycoprotein refolding. ENTPD5 expression is upregulated through two independent pathways: PI3-AKT axis 53 signaling and mutant p53 interactions.
54
ENTPD5 is believed to support cancer growth via two mechanisms. First, the high protein 55 synthesis demand of cancer cells puts the protein folding machinery under stress, including the machinery 56 to properly fold glycosylated proteins trafficked through the ER. ENTPD5 relieves ER stress in cancer 57 cells by providing UMP for the UDP-glucose antiporter, allowing for more cycles of glycoprotein folding 58 in the ER (Fig 1) 
193
Hits and hit analogs were (re)purchased from Chembridge for SAR studies. Compounds were 194 assayed at 5 µM, 10 µM, 20 µM, and 40 µM using the assay described above.
195
Malachite green assay 196 Malachite Green (MG) assay[17] for free phosphate was used to directly test ENTPD5 activity.
197
Standard curves for each preparation of malachite green were generated using known amounts of free 
Results
245
Recombinant expression and purification of ENTPD5. at position 39. The structure of ENTPD5 is predicted to contain two conserved disulfide bonds (Fig 2a) .
253
Cysteine-39 is a non-conserved cysteine that is predicted to not be required for proper protein folding, and 254 its absence should reduce the propensity for the formation of incorrect disulfide bridges, especially in the 255 process of refolding the enzyme. For bacterial expression, bacterial codon-optimized human ENTPD5 256 44-428 (B.ENTPD5) was cloned into pET14b vector with a C-term His 8 -tag (Fig 2a) . Recombinant 257 ENTPD5 was also produced in insect cells (I.ENTPD5) using BEVS. This expression system produced 258 natively active protein without denaturing, refolding, or shuffling of disulfide bonds. 
267
Both sources of purified protein appear the same size on SDS-PAGE (Fig 2b) and behave 268 similarly on gel filtration, corresponding to the expected monomeric size (Fig 2c) . The ~65 kDa band 269 observed in the B.ENTPD5 sample is BSA added post-purification for protein stability purposes. Maximum enzymatic activity was achieved using the I.ENTPD5 protein (Fig 2d) , corresponding to a 271~30% increase in k cat relative to that previously reported for refolded hENTPD5 purified from bacteria [13] .
272
High-throughput screening to identify inhibitors of ENTPD5.
273
To discover ENTPD5 inhibitors, a coupled enzyme assay was developed for high-throughput 274 screening. The ENTPD5 reaction (UDP  UMP + Pi) was coupled with uridine monophosphate kinase's 275 (UMPK) reaction with UMP (UMP + ATP  UDP + ADP) to create a futile catalytic cycle consuming 276 ATP (Fig 3a) . After one hour, the residual ATP was measured with firefly luciferase. UMPK 277 concentrations were chosen to ensure ENTPD5, not UMPK, was rate-limiting. The ATP concentration 278 was chosen to maximize signal with no ENTPD5 present, and the reaction time was optimized to remain 279 in the linear range of the assay. Initial UDP concentration was chosen to allow for multiple turnover 280 events on a single molecule in the cycle. Due to the availability of higher yields of the bacterially 281 produced enzyme, B.ENTPD5 was used for HTS and subsequent structure activity relationship studies.
282 21,000 compounds were screened in duplicate at 20 µM. The average Z' value of the 132-plate screen 283 was 0.73, indicating a robust assay [20] . Five compounds producing >25% reproducible inhibition of 284 ENTPD5 activity were selected for further analysis (0.02% hit rate) (Fig 3b, c) . 
290
Percent ENTPD5 inhibition by each hit is shown in parentheses. 294 displayed a dose-dependent inhibition of I.ENTPD5. Hit compounds 1a, 2a, and 2b were used as the basis for structure activity relationship studies, in 296 which ten analogs that were at least 80% structurally similar to the initial hits were tested against 297 ENTPD5 at 5, 10, 20 and 40 µM (Fig 4) . Analogs of compound 4 were not available from the supplier at 298 the time of SAR. All three analogs of compound 1a were inactive against ENTPD5, highlighting the 299 importance of a methyl group at position R 2 . The compound 2 series SAR demonstrates that substitutions 300 on the benzenesulfonamide are well tolerated (Fig 4, core A series) . However, replacing the 301 N-hydroxyphenyl group with an N-hydroxynapthalene leads to a drastic loss in potency (Fig 4, core B 302 series). 
291
Validation of ENTPD5 HTS hits
303
304
Close analogs of hits 1a (A) and 2a (B) were assayed with B.ENTPD5 to assess the effect of conservative 305 substitutions to the scaffolds. Compounds were assayed at 5, 10, 20, and 40 M using the coupled 306 enzyme HTS assay to determine IC 50 values. Data were fit by nonlinear regression.
307
The most potent compounds from each inhibitor scaffold, 1a and 2f, were re-assayed in the MG 308 assay at an expanded concentration range. Limited solubility of the hits prevented us from achieving a 309 concentration required for full inhibition of the ENPTD5 activity. Nevertheless, these studies revealed
310
IC 50 values of 3.14 µM and 1.54 µM for compounds 1a and compound 2f, respectively, and IC 50 >100 311 µM for inactive compound 1b (Fig 5) . 
326
EC 50 values of 0.47 µM and 3.12 µM were obtained for LNCaP and DU145 cells, respectively (Fig 6b) . 
332
To test the hypothesis that inhibition of ENTPD5 has an impact on cell growth due to the 333 reduction of protein glycosylation and to further investigate the utility of 1a as an effective molecular 334 probe, we immunoblotted for total O-glycosylation levels within LNCaP and DU145 cells following 24 335 hours of treatment at 10 µM of compound 1a and compound 2f. First we verified that untreated LNCaP 336 and DU145 cells have high levels of ENTPD5, Sp1, and O-glycosylation (Fig 7a) . Compound 1a, but not 337 compound 2f, reduced the amount of O-glycan present in the two prostate cell lines (Fig 7b, c) . The 338 decrease in O-glycan levels by compound 1a is consistent with the effects of ENTPD5 inhibition on the 339 glycoprotein refolding cycle. The inability of compound 2f to reduce O-glycan levels could be attributed 340 to low cell permeability but requires further investigation. experiments.
